To overcome these constrains, this trial purposefully chose non-sensitized and stable kidney transplant recipients who had been diagnosed with squamous cell skin carcinoma with poor prognosis characteristics, and used conversion to monotherapy with mTOR inhibitors as adjuvant to the dermatological therapy. Here, MTOR is linked to skin squamous cell carcinoma.